Michael Cecchini
Yale University Cancer Center LAO · Yale University · Assistant Professor of Medicine (Medical Oncology) Yale University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Michael Cecchini as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:19 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05691491 · Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and EffectivenessNational Cancer Institute (NCI) · recruiting · Advanced Malignant Solid Neoplasm, Advanced Microsatellite Stable Colorectal Carcinoma, Hematopoietic and Lymphatic System Neoplasm · principal investigator
- Ph1NCT05037149 · Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid TumorsSirnaomics · completed · Solid Tumor · principal investigator
- Ph2NCT04166435 · TMZ + Olaparib for MGMT Hypermethylated Colorectal CancerYale University · completed · Colorectal Cancer · principal investigator
- Ph1/Ph2NCT03008278 · Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by SurgeryNational Cancer Institute (NCI) · completed · Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Immunomodulatory Effects of Targeting DNA Repair with Novel Temozolomide Combinations in Colorectal CancerK08CA255465 · NCI · YALE UNIVERSITY · fiscal years 2021 to 2025 · $260,958 awarded in 2025Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Supplement to Extend Funds for Grant #UM1CA186689 VICKtOrY Early Clinical Trials ConsortiumUM1CA186689 · NCI · YALE UNIVERSITY · PI Patricia M. LoRusso · fiscal years 2014 to 2026Named on NCT05691491, NCT03008278
Most cited trial papers
Clinical-trial papers with this author name in colorectal cancer, ranked by citations from NIH iCite, fetched 2026-11-12 10:19 UTC. The ranking covers the 200 most relevant of 4 PubMed records, and a shared surname and initials can bring in a namesake. All 4 on PubMed